BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. “In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand growth of 10% year-over-year. Additionally, LINZESS net price was in-line with our expectations for the qu
Related Questions
Did the net price for LINZESS meet, exceed, or fall short of market expectations?
How does the $248 million U.S. net sales figure for LINZESS compare to analyst expectations?
Are there any upcoming regulatory milestones or product launches that could affect future earnings?
What are the key drivers behind the reported growth—price, volume, or mix?
What impact will the Q2 results have on the implied 12‑month target price for IRWD?
How does the reported guidance for full year 2025 compare with previous guidance and consensus estimates?
How does IRWD’s Q2 performance compare with its main competitors in the GI therapeutics space?
What was the year-over-year growth rate for LINZESS in Q2 2025 compared to the same period last year?
What is the underlying reason for the 10% EUTRx demand growth and is it sustainable?
Is there any indication of changes in the company's cost structure or operating expenses that could affect margins?
How might the current market sentiment (70) influence investor sentiment or trading volume in the short term?
What does the guidance imply about IRWD’s cash flow and profitability outlook for the remainder of 2025?